Fig. 3

Tumour volume measured by the IVIS imaging systems after different treatments. In vivo tumour growth and immunotherapy responses of individuals after a) standard care and b) novel TIGIT treatments. Anti-PD-1 single-armed treatment was presented in supplementary Fig. 5. Numbers indicate tumour-regression animals/total animals at completion. c Overall survival at the end of treatments (Day 30). N = 5–10 mice were utilized per treatment group